TABLE 1.
First author, year [ref.] | Length of treatment | Macrophages | Neutrophils | Eosinophils | Mast cells | Lymphocytes |
Verhoeven, 2002 [ 64 ] | 6 months (ICS) | = | = | = | = | = |
Hattotuwa, 2002 [ 61 ] | 3 months (ICS) | = | = | = | ↓ | = |
Barnes, 2006 [ 63 ] | 3 months (ICS/LABA) | = | X | X | =# | ↓ |
Bourbeau, 2007 [ 62 ] | 3 months (ICS) | = | = | = | X | = |
Reid, 2008 [ 59 ] | 6 months (ICS) | ↓ | ↑ | = | =# | = |
Lapperre, 2009 [ 60 ] | 6 months (ICS) | = | = | = | ↓ | ↓ |
6 months (ICS/LABA) | = | = | = | ↓ | ↓ | |
30 months (ICS) | = | = | ↑ | ↓ | ↓ | |
30 months (ICS/LABA) | = | = | ↓ | ↓ | ↑ |
=: no change; ↑: increase; ↓: decrease; X: not measured. LABA: long-acting β-agonist. #: trend for reduced mast cell numbers without reaching statistical significance.